REANDA-NEWS. July 06, 2015. Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces that it is hosting the Eighth Annual Adjuvants in Allergy Conference in Amsterdam

At the conference, Dr. Albert Roger Director of the Allergy Unit at Universitari Hospital Germans Trias Pujol, Badalona Spain, will present data from the Company's recent Acarovac efficacy study for the treatment against house dust mite allergy.  Acarovac has been Allergy Therapeutics strongest growing treatment in Spain this year and it is one of the Company's new generation of products developed to address the perennial allergy market with innovative and short-course therapies.     

The conference provides an outstanding opportunity for scientific debate and dialogue amongst 200 specialists in respiratory diseases and allergology from all over Europe and America.  New perspectives and innovations in allergy treatment will be presented by international key opinion leaders in order to initiate the process of global shared knowledge in these areas and ultimately lead to improvements in patient outcomes. 

There is an exciting programme of topics to facilitate in-depth discussions, which include, the impact for allergists on changes to the climate and migration patterns, the distribution of pollen counts and their annual patterns, the generation and maintenance of allergen specific T-cell tolerance, options and strategies for primary and secondary prevention of atopy and asthma, and the dramatic increase in the prevalence of allergic diseases.

Manuel Llobet, Chief Executive Officer, commented:

"Allergy Therapeutics is proud to host the Eighth Annual Adjuvants in Allergy Conference, a highly scientific open forum to discuss allergy topics with expert key opinion leaders and allergists from around the world.  The aim of the conference is to encourage the medical community to consider innovative solutions for patients suffering from allergies and we are excited to be at the forefront of these discussions."

For more information on the conference and a programme outline, please use the following link: http://www.allergytherapeutics.nl/files/2914/2167/1597/ATL_program.pdf